Latest Administration News

Page 73 of 164
PT Aneka Tambang Tbk (ANTAM) reported a remarkable 240% surge in net profit for the half year ended June 30, 2025, driven by robust gold and nickel sales amid a challenging mining sector.
Maxwell Dee
Maxwell Dee
29 Aug 2025
Astron Limited has finalized its move from Hong Kong to Australia, issuing new securities on a two-for-one basis and preparing for ASX trading starting September 1, 2025.
Maxwell Dee
Maxwell Dee
29 Aug 2025
Osteopore Limited reported a 6% increase in revenue to $1.56 million for the half-year ended June 2025, alongside a slight rise in net loss driven by expanded product development and compliance costs. The company secured key regulatory approvals and broadened its distribution footprint in Asia and the US.
Ada Torres
Ada Torres
29 Aug 2025
Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.
Ada Torres
Ada Torres
29 Aug 2025
Papyrus Australia reported a July 2025 cash flow update showing a stable cash position of AUD 303,000 and available funding supporting operations for over eight months. The company continues to manage its financing facilities prudently while navigating operational expenses.
Maxwell Dee
Maxwell Dee
29 Aug 2025
Bougainville Copper Limited posted a deeper half-year loss as it ramps up exploration and navigates ongoing legal disputes tied to its historic Panguna mine. The company also advances infrastructure remediation under a key government agreement.
Maxwell Dee
Maxwell Dee
29 Aug 2025
Althea Group Holdings reports a significant reduction in losses for FY25, driven by asset sales and strategic refocus on North American THC beverages. The company completed a $4 million capital raise and navigated leadership changes amid subsidiary liquidations.
Ada Torres
Ada Torres
29 Aug 2025
Cambium Bio reported a $3.84 million loss for FY25 but secured critical FDA approvals and ethics clearances to initiate Phase 3 trials of Elate Ocular®, supported by a $2.12 million capital raise.
Ada Torres
Ada Torres
29 Aug 2025
Adisyn Ltd reported a sharp increase in losses for FY25, driven by a 40% revenue drop and a costly acquisition, while securing significant new equity funding.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Adherium Limited reported a $12.68 million net loss for FY2025 as it pivots towards commercialising its smart inhaler technology in the US, supported by a $4.49 million capital raise.
Ada Torres
Ada Torres
29 Aug 2025
Zelira Therapeutics reported a significantly reduced loss of AUD 3.85 million for FY25, driven by clinical progress and strategic funding for its HOPE® cannabinoid medicines. The company also expanded its patent portfolio and commercial footprint across key markets.
Ada Torres
Ada Torres
29 Aug 2025
Paradigm Biopharmaceuticals marked FY25 with the launch of its global Phase 3 trial for its osteoarthritis drug iPPS, backed by strong FDA protocol approval and a $41 million funding facility. The company also broadened its pipeline with the acquisition of Pentacoxib™, targeting early-stage OA.
Ada Torres
Ada Torres
29 Aug 2025